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Available online 12 September 2015Inheritedmutations in the BRCA1 (breast cancer 1, early onset) gene
increase the risk of female breast and ovarian cancers. About 65% and
40% of females who inherit BRCA1 mutations will develop breast and
ovarian cancer, respectively (Antoniou et al., 2003). To address speciﬁc
roles of BRCA1 in the normal development and cancer pathogenesis, a
number of genetically modiﬁed mouse models have been developed.
It has been shown that mammary epithelium-speciﬁc inactivation of
Brca1 alone is insufﬁcient for cancer induction. However, mammary
carcinomas can be induced by concurrent inactivation of Brca1 together
with p53 (aka TP53/Trp53) gene, another tumor suppressor gene com-
monly inactivated in familial breast carcinomas. Similar to human
breast cancers mutant for BRCA1, mouse BRCA1/P53 deﬁcient tumors
are mainly basaloid and triple-negative (no expression of estrogen
receptor, progesterone receptor and HER/ERBB2 protein) (Liu et al.,
2007). Transplantation of the ovarian surface epithelium (OSE) cells null
for Brca1 and p53 genes resulted in the formation of carcinomas, which
closely resembled high-grade serous ovarian carcinomas (HGSOC), the
most common type of ovarian carcinoma (Orsulic et al., 2002).
Albeit highly valuable, the models used in those studies were
focused on genetic modiﬁcation in target cells and did not allow for
direct testing of the role of non-autonomous factors in the pathogenesis
of cancers associated with BRCA1 deﬁciency. To address this problem,
Liu et al., 2015 developed newmousemodels allowing Cre-loxPmediat-
ed gene modiﬁcations in tissues expressing the Müllerian inhibiting
substance receptor type 2 (Mis2r, aka anti-Müllerian hormone receptor
type 2) and follicle stimulating hormone receptor (Fshr). The authors
established patterns of expression directed by theMis2r and truncated
Fshrpromoters, and inactivatedﬂoxed Brca1 and p53 via Cre recombinase
driven by these promoters. Consistent with the detected expression of
Mis2r and Fshr transgenes in the mammary gland, the authors observed
the formation of Brca1 and p53 deﬁcient tumors featuring preferentiallyom.2015.08.034.
. This is an open access article underbasaloid triple negative phenotype. Interestingly,while transgene expres-
sion was observed in a number of other tissues, including the renal
tubules, the cervix, the uterine horns, the uterine tubes (aka oviducts or
fallopian tubes), and the ovaries, only few of these tissues have shown
neoplastic lesions. This suggests that BRCA1 and P53 functions may be
especially critical for tumor prevention in certain cells types.
Another interesting aspect of the paper is the observation of
neoplastic lesions associated with endosalpingiosis, a condition in
which the tubal epithelium is found outside of the uterine tube. Ovarian
carcinoma's tissue of origin remains debatable. The original pathological
observations suggested that EOC arises from the OSE and from cysts
formed after OSE entrapment during ovulation (Auersperg et al.,
2008; Flesken-Nikitin et al., 2014). This model has been supported by
results from experimental transformation of rat, mouse, and human
OSE cells, induction of ovarian carcinoma by OSE-targeted conditional
genetic alterations in genetically modiﬁed mice and by genetic analysis
of human ovarian cystic inclusions (Orsulic et al., 2002; Flesken-Nikitin
et al., 2014; Auersperg, 2013). The broad variety of ovarian carcinoma
phenotypes are usually attributed to the origin of the OSE from the
coelomic epithelium. During embryonic development, this epithelium
also gives rise to the Müllerian (paramesonephric) ducts, which, in
turn, differentiate into the epithelia of the uterine tube, endometrium
and endocervix (Flesken-Nikitin et al., 2014). Based on morphological
similarities of HGSOC to the tubal epithelium, as well as ﬁndings of
mutant P53 in atypical lesions of the uterine tube (serous tubal
intraepithelial carcinomas, STICs), it was proposed that ovarian carcino-
mamay derive from that epithelium (Medeiros et al., 2006). Supporting
this possibility, it has been shown that p53, Brca1 and Pten inactivations
in the PAX8-expressing secretory tubal epithelium cells lead to HGSOC
in genetically modiﬁed mice (Perets et al., 2013). Previously, Dr. Louis
Dubeau, the senior author of the current manuscript, has proposed
that ovarian carcinoma may also arise from other components of the
secondary Müllerian system such as endosalpingiosis (Dubeau, 2008).
Although only very few endosalpingiosis-associated lesions have been
observed in the current manuscript, their ﬁnding provides a proof
of concept and justiﬁes the need for a particular attention to the
endosalpingiosis as a putative place of origin of some ovarian carcinomas.
As stated by the authors, in the current conﬁguration, themodels are
not suitable for the discrimination between cell autonomous and non-
autonomous mechanisms of cancer formation; however, the value of
these models is in their applicability to transplantation assays. It will
be very interesting to determine if transplantations of non-mutant
mammary epithelium and/or Müllerian derivatives into mice carryingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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will result in carcinogenesis. Such studies may provide essential new in-
sights into the pathogenesis of familial cancers associated with BRCA1
mutations and facilitate the development of new therapeutic approaches.
Disclosure
This paper is supported by the funding from the National Institute
of Health/National Cancer Institute (CA182413), the New York Stem
Cell Science (NYSTEM, C028125) and Ovarian Cancer Research Fund
(327516).
References
Antoniou, A., Pharoah, P.D.P., Narod, S., et al., 2003. Average risks of breast andovarian cancer
associatedwith BRCA1 or BRCA2mutations detected in case series unselected for family
history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117–1130.Auersperg, N., 2013. Ovarian surface epithelium as a source of ovarian cancers: unwar-
ranted speculation or evidence-based hypothesis? Gynecol. Oncol. 130, 246–251.
Auersperg, N., Woo, M.M., Gilks, C.B., 2008. The origin of ovarian carcinomas: a develop-
mental view. Gynecol. Oncol. 110, 452–454.
Dubeau, L., 2008. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 9,
1191–1197.
Flesken-Nikitin, A., Odai-Afotey, A.A., Nikitin, A.Y., 2014. Role of the stem cell niche in the
pathogenesis of epithelial ovarian cancers. Mol. Cell Oncol. 1, e963435.
Liu, X., Holstege, H., van der Gulden, H., et al., 2007. Somatic loss of BRCA1 and p53 inmice
induces mammary tumors with features of human BRCA1-mutated basal-like breast
cancer. Proc. Natl. Acad. Sci. U. S. A. 104, 12111–12116.
Liu, Y., Yen, H.-Y., Austria, T., et al., 2015. A mouse model that reproduces the develop-
mental pathways and site speciﬁcity of the cancers associated with the human
brca1 mutation carrier state. EBioMedicine 2, 1318–1330.
Medeiros, F., Muto, M.G., Lee, Y., et al., 2006. The tubal ﬁmbria is a preferred site for early
adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg.
Pathol. 30, 230–236.
Orsulic, S., Li, Y., Soslow, R.A., et al., 2002. Induction of ovarian cancer by deﬁned multiple
genetic changes in a mouse model system. Cancer Cell 1, 53–62.
Perets, R., Wyant, G.A., Muto, K.W., et al., 2013. Transformation of the fallopian tube secre-
tory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten Models.
Cancer Cell 24, 751–765.
